IN2014DN06911A - - Google Patents

Info

Publication number
IN2014DN06911A
IN2014DN06911A IN6911DEN2014A IN2014DN06911A IN 2014DN06911 A IN2014DN06911 A IN 2014DN06911A IN 6911DEN2014 A IN6911DEN2014 A IN 6911DEN2014A IN 2014DN06911 A IN2014DN06911 A IN 2014DN06911A
Authority
IN
India
Prior art keywords
dioleylphosphatidylcholine
tocopherol
falls
range
blend concentration
Prior art date
Application number
Inventor
Kazuhito Yamada
Arto Urtti
Mechthild Burmester
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of IN2014DN06911A publication Critical patent/IN2014DN06911A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

A drug dissolved non aqueous liquid composition comprising a drug dioleylphosphatidylcholine tocopherol and an organic solvent wherein the ratio of the blend concentration of dioleylphosphatidylcholine to that of tocopherol falls within the range from 75/25 to 25/75 the blend concentration of dioleylphosphatidylcholine falls within the range from 15 to 85% (w/w) and the blend concentration of tocopherol falls within the range from 15 to 85% (w/w). The phase of the non aqueous liquid composition can be changed into a non lamellar liquid crystal upon the contact with water a phosphate buffer a body fluid a tear fluid or a vitreous fluid.
IN6911DEN2014 2012-01-31 2013-01-30 IN2014DN06911A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012018062 2012-01-31
PCT/JP2013/051951 WO2013115201A1 (en) 2012-01-31 2013-01-30 Non-aqueous liquid composition

Publications (1)

Publication Number Publication Date
IN2014DN06911A true IN2014DN06911A (en) 2015-05-15

Family

ID=48905235

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6911DEN2014 IN2014DN06911A (en) 2012-01-31 2013-01-30

Country Status (12)

Country Link
US (1) US20150011518A1 (en)
EP (1) EP2810657B1 (en)
JP (1) JP2013177372A (en)
KR (1) KR20150000874A (en)
CN (1) CN104080478A (en)
CA (1) CA2861261A1 (en)
EA (1) EA201491453A1 (en)
IN (1) IN2014DN06911A (en)
PH (1) PH12014501689A1 (en)
SG (2) SG11201404230QA (en)
TW (1) TW201336526A (en)
WO (1) WO2013115201A1 (en)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
EP0975331A1 (en) * 1997-04-17 2000-02-02 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4496406B2 (en) 2003-03-07 2010-07-07 参天製薬株式会社 Novel compound having 4-pyridylalkylthio group as a substituent
CN1897918A (en) * 2003-11-17 2007-01-17 阿尔萨公司 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
JP4626353B2 (en) 2004-02-17 2011-02-09 参天製薬株式会社 Novel cyclic compound having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced
ATE401054T1 (en) * 2004-06-04 2008-08-15 Camurus Ab LIQUID DEPOSIT FORMULATIONS
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
CA2594711C (en) * 2005-01-14 2012-11-06 Camurus Ab Somatostatin analogue formulations
EP1845942B1 (en) * 2005-01-14 2014-04-09 Camurus Ab Gnrh analogue formulations
AU2005325510B2 (en) * 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
JP4585978B2 (en) 2005-03-03 2010-11-24 参天製薬株式会社 Novel cyclic compounds having a quinolylalkylthio group
JP4834441B2 (en) 2005-03-31 2011-12-14 参天製薬株式会社 Novel cyclic compounds having pyrimidinylalkylthio groups
PL1888031T3 (en) * 2005-06-06 2013-04-30 Camurus Ab Glp-1 analogue formulations
JP4825636B2 (en) 2005-09-14 2011-11-30 参天製薬株式会社 Novel 1,2-dihydroquinoline derivatives having glucocorticoid receptor binding activity
JP5054996B2 (en) 2006-03-14 2012-10-24 参天製薬株式会社 Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity
PL2085388T3 (en) 2006-11-14 2013-01-31 Santen Pharmaceutical Co Ltd Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents
US8063034B2 (en) 2007-01-29 2011-11-22 Santen Pharmaceutical Co., Ltd. Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
EP2151436B1 (en) 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
JP2009084274A (en) 2007-09-13 2009-04-23 Santen Pharmaceut Co Ltd New 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivative
BR112012001159A2 (en) 2009-07-17 2016-03-01 Santen Pharmaceutical Co Ltd 2 - [[[2 - [(hydroxyacetyl) amino] -4-pyridinyl] methyl] thio] - n - [4- (trifluoromethoxy) phenyl] -3-pyridinecarboxamide benzenesulfonate, polymorph crystal thereof, and methods for producing the same
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Also Published As

Publication number Publication date
KR20150000874A (en) 2015-01-05
EP2810657A4 (en) 2015-07-29
TW201336526A (en) 2013-09-16
EA201491453A1 (en) 2014-12-30
PH12014501689A1 (en) 2014-10-20
EP2810657A1 (en) 2014-12-10
WO2013115201A1 (en) 2013-08-08
EP2810657B1 (en) 2016-09-21
US20150011518A1 (en) 2015-01-08
JP2013177372A (en) 2013-09-09
SG11201404230QA (en) 2014-10-30
SG10201606271RA (en) 2016-09-29
CN104080478A (en) 2014-10-01
CA2861261A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
AU348190S (en) Hitch ball mount
PH12015500115B1 (en) Glucagon analogues
MY170623A (en) Additive for preparing suede on monocrystalline silicon chip and use method thereof
MX370903B (en) Stable percarboxylic acid compositions and uses thereof.
MA37975A1 (en) Glucosylceramide synthase inhibitors
CL2015003738A1 (en) Stable liquid formulation of amg-416 (velcalcetide)
EP3083925A4 (en) Stable liquid compositions containing enzymes and peroxides
GB201208238D0 (en) Foam control formulations
CA2862669A1 (en) Application of fluorescent dyes to trace and quantify chemical dosage in industrial wastewater
IN2014MN01553A (en)
ZA201504341B (en) Biodegradable additive concentrate improving the lubricity of aqueous sludges, use thereof and aqueous sludge for drilling
AU352917S (en) Trailer jack
MX2013008277A (en) Bromfenac aqueous liquid composition having preservative efficiency.
IN2014DN06911A (en)
PH12014501307A1 (en) Liquid activation system
AR097717A1 (en) GELATINIZABLE COMPOSITION WITH HIGH SALT CONTENT FOR WELL TREATMENT
CL2015001397A1 (en) Compounds derived from 4-amino-7,8-dihydropyrimido [5,4-f] [1,4] oxazepin-5 (6h) -one, diacylglycerol acyltransferase inhibitors; Pharmaceutical composition and use in the treatment of obesity.
GR1008101B (en) Drinkable folic acid solutions
BR112015007885A2 (en) inorganic nutritional composition of iron
WO2011092655A3 (en) Mentha suaveolens essential oil and therapeutic activities thereof
MX369071B (en) Methods of preventing emulsification of crude oil in well bore treatment fluids.
FENG The Personalized Society and the Mao Yushi Phenomenon
AU352959S (en) Trailer jack
AU201215085S (en) Floatation device
AU352595S (en) Label for hitch match system